tetano
Editor, Senior Moderator
Clin Immunol
. 2022 Apr 27;238:109024.
doi: 10.1016/j.clim.2022.109024. Online ahead of print.
Myeloid-derived suppressor cells in COVID-19: A review
Yuliya V Perfilyeva[SUP] 1 [/SUP], Yekaterina O Ostapchuk[SUP] 2 [/SUP], Raikhan Tleulieva[SUP] 2 [/SUP], Aykin Kali[SUP] 3 [/SUP], Nurshat Abdolla[SUP] 3 [/SUP], Vladimir K Krasnoshtanov[SUP] 4 [/SUP], Anastassiya V Perfilyeva[SUP] 5 [/SUP], Nikolai N Belyaev[SUP] 6 [/SUP]
Affiliations
Abstract
Coronavirus disease 2019 (COVID-19) is a potentially life-threatening infection characterized by excessive inflammation, coagulation disorders and organ damage. A dysregulated myeloid cell compartment is one of the most striking immunopathologic signatures of this newly emerged infection. A growing number of studies are reporting on the expansion of myeloid cells with immunoregulatory activities in the periphery and airways of COVID-19 patients. These cells share phenotypic and functional similarities with myeloid-derived suppressor cells (MDSCs), which were first described in cancer patients. MDSCs are a heterogeneous population of pathologically activated myeloid cells that exert immunosuppressive activities against mainly effector T cells. The increased frequency of these cells in COVID-19 patients suggests that they are involved in immune regulation during this infection. In this article, we review the current findings on MDSCs in COVID-19 and discuss the complex role of these cells in the immunopathology of COVID-19.
Keywords: COVID-19; Immunopathology; Myeloid-derived suppressor cell; SARS-CoV-2.
. 2022 Apr 27;238:109024.
doi: 10.1016/j.clim.2022.109024. Online ahead of print.
Myeloid-derived suppressor cells in COVID-19: A review
Yuliya V Perfilyeva[SUP] 1 [/SUP], Yekaterina O Ostapchuk[SUP] 2 [/SUP], Raikhan Tleulieva[SUP] 2 [/SUP], Aykin Kali[SUP] 3 [/SUP], Nurshat Abdolla[SUP] 3 [/SUP], Vladimir K Krasnoshtanov[SUP] 4 [/SUP], Anastassiya V Perfilyeva[SUP] 5 [/SUP], Nikolai N Belyaev[SUP] 6 [/SUP]
Affiliations
- PMID: 35489643
- PMCID: PMC9042722
- DOI: 10.1016/j.clim.2022.109024
Abstract
Coronavirus disease 2019 (COVID-19) is a potentially life-threatening infection characterized by excessive inflammation, coagulation disorders and organ damage. A dysregulated myeloid cell compartment is one of the most striking immunopathologic signatures of this newly emerged infection. A growing number of studies are reporting on the expansion of myeloid cells with immunoregulatory activities in the periphery and airways of COVID-19 patients. These cells share phenotypic and functional similarities with myeloid-derived suppressor cells (MDSCs), which were first described in cancer patients. MDSCs are a heterogeneous population of pathologically activated myeloid cells that exert immunosuppressive activities against mainly effector T cells. The increased frequency of these cells in COVID-19 patients suggests that they are involved in immune regulation during this infection. In this article, we review the current findings on MDSCs in COVID-19 and discuss the complex role of these cells in the immunopathology of COVID-19.
Keywords: COVID-19; Immunopathology; Myeloid-derived suppressor cell; SARS-CoV-2.